Multidrug-resistant tuberculosis

Audiological Evaluation of Patients Taking Kanamycin for Multidrug Resistant Tuberculosis

Introduction: The incidence of multidrug resistant tuberculosis is increasing in developing countries. Aminoglycosides are an integral part of second-line drugs, however ototoxicity is a major limitation for their use. This study aims to determine the extent of hearing loss in patients taking one of the commonly prescribed drugs for Multidrug resistant tuberculosis (MDR-TB), Kanamycin, at a Gov...

Multidrug-resistant tuberculosis today.

Editorials 78 The World Health Organization (WHO) and its partners have long conducted efforts to improve tuberculosis (TB) case surveillance and programme monitoring and evaluation. WHO's 2011 report on global TB control 1 provided the most reliable information ever generated on the burden of disease and death caused by TB and multidrug-resistant TB (i.e. disease marked by in vitro resistance ...

Multidrug-resistant tuberculosis.

Multidrug-resistant tuberculosis (MDR-TB) caused by Mycobacterium tuberculosis resistant to both isoniazid and rifampicin with or without resistance to other drugs is among the most worrisome elements of the pandemic of antibiotic resistance. Globally, about three per cent of all newly diagnosed patients have MDR-TB. The proportion is higher in patients who have previously received antitubercul...

Multidrug-resistant tuberculosis.

Despite the efforts made worldwide to reduce the number of cases of drug-susceptible tuberculosis, multidrug-resistant tuberculosis (MDR-TB) constitutes an important public health issue. Around 440,000 new cases of MDR-TB are estimated annually, although in 2008 only 7% of these (29,423 cases) were notified. The laboratory tests for diagnosing resistance may be phenotypic (based on culture grow...

Multidrug resistant tuberculosis.